Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.33 |
| ▸ | IL1B | P01584 | 4/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21550362 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25281149 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25263000 | 0.85 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL477253 | 0.80 | — | — | |
| SCHEMBL18247609 | 0.79 | PKM (0.38) | IL1BDGAT2 | |
| SCHEMBL21813466 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL5573261 | 0.78 | — | — | |
| Acetic Acid SCHEMBL28524681 | 0.78 | HPSE (0.37) | IL1BDGAT2 | |
| SCHEMBL23113716 | 0.78 | EPHX2 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27212481 | 0.78 | EPHX2 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4157446-A1 | KINASE INHIBITORS | GB002, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329294-B2 | Pyrazolopyrimidine inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | CHRNB2 4388/4885CHRNA4 3342/4885CHRNB4 3856/4885 |
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | CHRNB2 4296/4885CHRNA4 4609/4885CHRNB4 4666/4885 |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | CHRNB2 4820/4885CHRNA4 4828/4885CHRNB4 4877/4885 |
| US-20180051028-A1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | CHRNB2 4388/4885CHRNA4 3342/4885CHRNB4 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.